GlassScriptPhysician profile
Paul A Elliott
NPI 1801876669
$20,208.45
in general payments reported to CMS, 2019-2025
67 companies · $4,548 in 2025
The $4,548 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $2,209 · 2021: $2,682 · 2022: $2,195 · 2023: $3,012 · 2024: $3,390 · 2025: $4,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,639.43 |
| Education | $310.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,999.78 | 2021-2025 | |
| Biogen, INC. | $1,702.51 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,646.92 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Emd Serono, INC. | $1,325.49 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,293.48 | 2019-2025 | |
| Pfizer INC. | $935.32 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $919.20 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $696.90 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Mdd US Operations, LLC | $660.50 | 2019-2025 | Apokyn, Apokyn |
| Eisai INC. | $573.79 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $568.66 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $519.47 | 2019-2025 | Crexont, Rytary, Ongentys |
| Lundbeck LLC | $504.67 | 2020-2025 | Vyepti, Rexulti |
| Amgen INC. | $497.73 | 2019-2025 | Uplizna |
| Harmony Biosciences LLC | $434.22 | 2020-2025 | Wakix |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.